Familial Mediterranean fever is a rare disorder but is usually easy to manage using colchicine. The publication of a severity score could serve as a useful reminder to rheumatologists about this disease and the difficulties in assessing its severity.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Ergebnisse der systematischen Literatursuche als Grundlage für die „evidenzbasierten Therapieempfehlungen für FMF-Patienten mit unzureichendem Ansprechen bzw. Unverträglichkeit auf Kolchizin“ der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Rheumatologie
Zeitschrift für Rheumatologie Open Access 30 September 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tunca, M. et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84, 1–11 (2005).
Ozen, S. et al. EULAR recommendations for the management of familial Mediterranean fever. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-208690, (2016).
Demirkaya, E. et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-208671, (2016).
Fujikura, K. Global epidemiology of familial Mediterranean fever mutations using population exome sequences. Mol. Genet. Genomic Med. 3, 272–282 (2015).
Xu, H. et al. Innate immune sensing of bacterial modifications of rho GTPases by the pyrin inflammasome. Nature 513, 237–241 (2014).
Akar, S. et al. Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine (Baltimore) 91, 131–136 (2012).
Ben-Chetrit, E. & Levy, M. Colchicine: 1998 update. Semin. Arthritis Rheum. 28, 48–59 (1998).
Eroglu, F. K., Besbas, N., Topaloglu, R. & Ozen, S. Treatment of colchicine-resistant familial Mediterranean fever in children and adolescents. Ann. Rheum. Dis. 35, 1733–1737 (2015).
Twig, G. et al. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann. Rheum. Dis. 73, 704–709 (2014).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lachmann, H., Brogan, P. When is familial Mediterranean fever 'severe'?. Nat Rev Rheumatol 12, 256–258 (2016). https://doi.org/10.1038/nrrheum.2016.55
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.55
This article is cited by
-
Ergebnisse der systematischen Literatursuche als Grundlage für die „evidenzbasierten Therapieempfehlungen für FMF-Patienten mit unzureichendem Ansprechen bzw. Unverträglichkeit auf Kolchizin“ der Gesellschaft für Kinder- und Jugendrheumatologie und der Deutschen Gesellschaft für Rheumatologie
Zeitschrift für Rheumatologie (2020)
-
Evidenzbasierte Therapieempfehlungen für das familiäre Mittelmeerfieber
Zeitschrift für Rheumatologie (2019)
-
Detection of Familial Mediterranean Fever attacks by using a connected activity tracker and assessment of impact of attacks to daily physical activities: a pilot study
Clinical Rheumatology (2019)
